Endocrine therapy for breast cancer: A tough pill to swallow

Menopause

Volumn 20, Issue 7, 2013, Pages 714-716

  Reynolds, Kerry L ^a   Higgins, Michaela J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; TAMOXIFEN;

3' UNTRANSLATED REGION; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DISTANT METASTASIS; EDITORIAL; FOLLOW UP; HUMAN; MEDICATION COMPLIANCE; POSTMENOPAUSE; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SELF REPORT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 84879975467     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182955b77     Document Type: Editorial

References (25)

1. Emanuel EJ. Shortchanging cancer patients. New York Times 2011.
2. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518.
4. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
5. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529-1542.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
7. Doggrell SA. Adherence to oral endocrine treatments in women with breast cancer: can it be improved? Breast Cancer Res Treat 2011;129: 299-308.
8. Hadji P, Ziller V, Kyvernitakis J, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013;138:185-191.
9. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-606.
10. Bell RJ, Schwarz M, Fradkin P, Robinson PJ, Davis SR. Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Menopause 2013;20:721-726.
11. Bell RJ, Fradkin P, Schwarz M, Davis SR. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 2013;20:15-21.
12. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
13. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [epub ahead of print]. Lancet 2012.
14. Myrick ME, Schmid SM, Kilic N, Güth U. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer. Acta Oncol 2012;51:247-253.
15. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012;30:936-942.
16. Liu M, Wang L, Bongartz T, et al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) geneYmediated regulation of cytokine expression. Breast Cancer Res 2012;14:R41.
17. Font R, Espinas JA, Gil-Gil M, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012;107:1249-1256.
18. Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012;23:882-890.
19. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8:155-161.
20. Hadji P, Blettner M, Harbeck N, et al. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer [epub ahead of print]. Ann Oncol 2013.
21. Yu KD, Zhou Y, Liu GY, et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support programin improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 2012;134:307-313.
22. Institute NC. NCI QuitPal App. Available at: http://www.smokefree.gov. Accessed May 6, 2013.
23. Villarreal-Garza C, Cortes J, Andre F, Verma S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 2012;23:2526-2535.
24. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-2637.
25. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011; 366:520-529.